Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients.

Meng Y, Li H, Hua R, Wang H, Lu J, Yu X, Zhang C.

Sci Rep. 2015 Oct 27;5:15546. doi: 10.1038/srep15546.

2.

Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies.

Kang JH, Ryoo NY, Shin DW, Trojanowski JQ, Shaw LM.

Korean J Physiol Pharmacol. 2014 Dec;18(6):447-56. doi: 10.4196/kjpp.2014.18.6.447. Epub 2014 Dec 30. Review.

3.

Frequency of the apolipoprotein E ε4 allele in a memory clinic cohort in Beijing: a naturalistic descriptive study.

Wang X, Wang H, Li H, Li T, Yu X.

PLoS One. 2014 Jun 10;9(6):e99130. doi: 10.1371/journal.pone.0099130. eCollection 2014.

4.

Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria.

Ferreira D, Perestelo-Pérez L, Westman E, Wahlund LO, Sarría A, Serrano-Aguilar P.

Front Aging Neurosci. 2014 Mar 24;6:47. doi: 10.3389/fnagi.2014.00047. eCollection 2014. Review.

6.

Effects of NR1H3 genetic variation on the expression of liver X receptor α and the progression of Alzheimer's disease.

Natunen T, Martiskainen H, Sarajärvi T, Helisalmi S, Pursiheimo JP, Viswanathan J, Laitinen M, Mäkinen P, Kauppinen T, Rauramaa T, Leinonen V, Alafuzoff I, Haapasalo A, Soininen H, Hiltunen M.

PLoS One. 2013 Nov 20;8(11):e80700. doi: 10.1371/journal.pone.0080700. eCollection 2013.

7.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1150-73. Review.

8.

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia.

Spitzer P, Schieb H, Kamrowski-Kruck H, Otto M, Chiasserini D, Parnetti L, Herukka SK, Schuchhardt J, Wiltfang J, Klafki HW.

Int J Alzheimers Dis. 2011;2011:739847. doi: 10.4061/2011/739847. Epub 2011 Nov 24.

9.

Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease.

Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2012 Aug;33(8):1599-608. doi: 10.1016/j.neurobiolaging.2011.05.005. Epub 2011 Jun 17.

10.

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Acta Neuropathol. 2011 May;121(5):597-609. doi: 10.1007/s00401-011-0808-0. Epub 2011 Feb 11.

11.

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance.

Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H; North American Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2012 Jul;33(7):1203-14. doi: 10.1016/j.neurobiolaging.2010.10.019. Epub 2010 Dec 14.

12.

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

Mattsson N, Zetterberg H, Blennow K.

Int J Alzheimers Dis. 2010 Jul 8;2010. pii: 610613. doi: 10.4061/2010/610613.

13.

Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.

Seppälä TT, Herukka SK, Hänninen T, Tervo S, Hallikainen M, Soininen H, Pirttilä T.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1123-7. doi: 10.1136/jnnp.2010.205757. Epub 2010 May 16.

14.

Tau as a biomarker of neurodegenerative diseases.

Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, Caillet-Boudin ML, Pasquier F, Maurage CA, Sablonnière B, Vanmechelen E, Buée L.

Biomark Med. 2008 Aug;2(4):363-84. doi: 10.2217/17520363.2.4.363.

15.

Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia.

Sonnen JA, Montine KS, Quinn JF, Breitner JC, Montine TJ.

J Alzheimers Dis. 2010;19(1):301-9. doi: 10.3233/JAD-2010-1236. Review.

16.

Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease.

Plant C, Teipel SJ, Oswald A, Böhm C, Meindl T, Mourao-Miranda J, Bokde AW, Hampel H, Ewers M.

Neuroimage. 2010 Mar;50(1):162-74. doi: 10.1016/j.neuroimage.2009.11.046. Epub 2009 Dec 2.

17.

Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease.

Grothe M, Zaborszky L, Atienza M, Gil-Neciga E, Rodriguez-Romero R, Teipel SJ, Amunts K, Suarez-Gonzalez A, Cantero JL.

Cereb Cortex. 2010 Jul;20(7):1685-95. doi: 10.1093/cercor/bhp232. Epub 2009 Nov 4.

18.

Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ.

Exp Gerontol. 2010 Jan;45(1):30-40. doi: 10.1016/j.exger.2009.10.010. Epub 2009 Oct 22. Review.

19.

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K.

Exp Neurol. 2010 Jun;223(2):334-46. doi: 10.1016/j.expneurol.2009.09.024. Epub 2009 Oct 6. Review.

20.

Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Robeson RH, Siegel AM, Dunckley T.

Biomark Insights. 2008 Feb 9;3:73-86.

Supplemental Content

Support Center